Literature DB >> 1741127

Retinal hemangioblastoma. A histologic, immunohistochemical, and ultrastructural evaluation.

H E Grossniklaus1, J W Thomas, N Vigneswaran, W H Jarrett.   

Abstract

The authors evaluated the histologic, immunohistochemical, and ultrastructural characteristics of two eyes with retinal hemangioblastoma from patients with von Hippel-Lindau and von Hippel disease. Results of histologic evaluation showed the eyes to have degenerative changes and residual retinal hemangioblastoma. Immunohistochemical stains performed for MAC-387, factor XIIIa, lysozyme, alpha 1 anti-chymotrypsin (histiocyte markers), factor VIII-associated antigen, ulex europeaus (endothelial markers), neuron-specific enolase, chromogranin, neurofilament (neuroectodermal/neural/neuroendocrine markers) and glial fibrillary acid protein (glial marker) showed normal retinal vascular endothelium, neurons, and glial cells to stain where expected. Vascular endothelium in the retinal hemangioblastomas stained for factor VIII and ulex europeaus. Interstitial cells in the stroma of the tumors failed to stain for the histiocyte markers, chromogranin, and neurofilament. The stromal cells stained for glial fibrillary acid protein and neuron specific enolase. Ultrastructural findings in both eyes included endothelial/pericyte-lined vascular channels, elongated stromal cells, and plump, vacuolated stromal cells with ultrastructural features consistent with glial cells. This study supports the concept that retinal hemangioblastoma is composed of a proliferation of capillaries and glial cells.

Entities:  

Mesh:

Year:  1992        PMID: 1741127     DOI: 10.1016/s0161-6420(92)32024-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

Review 1.  Von Hippel-Lindau disease.

Authors:  E R Maher; A T Moore
Journal:  Br J Ophthalmol       Date:  1992-12       Impact factor: 4.638

2.  Rb1/Rbl1/Vhl loss induces mouse subretinal angiomatous proliferation and hemangioblastoma.

Authors:  Ran Wei; Xiang Ren; Hongyu Kong; Zhongping Lv; Yongjiang Chen; Yunjing Tang; Yujiao Wang; Lirong Xiao; Tao Yu; Sabiha Hacibekiroglu; Chen Liang; Andras Nagy; Rod Bremner; Danian Chen
Journal:  JCI Insight       Date:  2019-11-14

Review 3.  Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.

Authors:  Chi-Chao Chan; Atif Ben Daniel Collins; Emily Y Chew
Journal:  Retina       Date:  2007-01       Impact factor: 4.256

4.  Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations.

Authors:  Emily Ying Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 5.  Central nervous system capillary haemangioblastoma: the pathologist's viewpoint.

Authors:  Mahmoud R Hussein
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

6.  Retinal function in the von Hippel-Lindau disease.

Authors:  Wojciech Lubiński; Karol Krzystolik; Cezary Cybulski; Zbigniew Szych; Krzysztof Penkala; Olgierd Palacz; Jan Lubiński
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

7.  Ocular clusterin expression in von Hippel-Lindau disease.

Authors:  Min Zhou; Defen Shen; James E Head; Emily Y Chew; Patricia Chévez-Barrios; W Richard Green; Chi-Chao Chan
Journal:  Mol Vis       Date:  2007-11-15       Impact factor: 2.367

8.  Giant Cell Astrocytoma of the Retina in a 1-Month-Old Infant.

Authors:  Cecilia S Jung; G Baker Hubbard; Hans E Grossniklaus
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2009-11-02       Impact factor: 1.402

9.  Pathology characteristics of ocular von Hippel-Lindau disease with neovascularization of the iris and cornea: a case report.

Authors:  Shida Chen; Emily Y Chew; Chi-Chao Chan
Journal:  J Med Case Rep       Date:  2015-03-25

Review 10.  An Update on the Ophthalmologic Features in the Phakomatoses.

Authors:  Solmaz Abdolrahimzadeh; Andrea Maria Plateroti; Santi Maria Recupero; Alessandro Lambiase
Journal:  J Ophthalmol       Date:  2016-07-17       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.